USA - NASDAQ:SHC - US83601L1026 - Common Stock
The current stock price of SHC is 16.86 USD. In the past month the price increased by 6.64%. In the past year, price increased by 9.55%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.56 | 216.18B | ||
| DHR | DANAHER CORP | 28.92 | 159.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 148.65 | 48.49B | ||
| A | AGILENT TECHNOLOGIES INC | 27.16 | 41.97B | ||
| IQV | IQVIA HOLDINGS INC | 19.23 | 37.49B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.07 | 29.55B | ||
| WAT | WATERS CORP | 29.39 | 21.40B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 42.07 | 21.39B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.32 | 17.00B | ||
| TEM | TEMPUS AI INC | N/A | 15.50B | ||
| ILMN | ILLUMINA INC | 24.06 | 15.39B | ||
| ICLR | ICON PLC | 13.5 | 13.85B |
Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. The company is headquartered in Broadview Heights, Ohio and currently employs 3,000 full-time employees. The company went IPO on 2020-11-20. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
SOTERA HEALTH CO
9100 South Hills Blvd, Suite 300, Suite 300
Broadview Heights OHIO 44147 US
CEO: Michael B. Petras
Employees: 3000
Phone: 14402621410
Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. The company is headquartered in Broadview Heights, Ohio and currently employs 3,000 full-time employees. The company went IPO on 2020-11-20. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
The current stock price of SHC is 16.86 USD. The price decreased by -0.24% in the last trading session.
SHC does not pay a dividend.
SHC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
SOTERA HEALTH CO (SHC) operates in the Health Care sector and the Life Sciences Tools & Services industry.
SOTERA HEALTH CO (SHC) has a market capitalization of 4.79B USD. This makes SHC a Mid Cap stock.
The outstanding short interest for SOTERA HEALTH CO (SHC) is 4.19% of its float.
ChartMill assigns a technical rating of 9 / 10 to SHC. When comparing the yearly performance of all stocks, SHC is one of the better performing stocks in the market, outperforming 83.07% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to SHC. While SHC belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months SHC reported a non-GAAP Earnings per Share(EPS) of 0.72. The EPS decreased by -8.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.13% | ||
| ROA | 0.75% | ||
| ROE | 4.7% | ||
| Debt/Equity | 4.49 |
11 analysts have analysed SHC and the average price target is 16.73 USD. This implies a price decrease of -0.78% is expected in the next year compared to the current price of 16.86.
For the next year, analysts expect an EPS growth of 13.43% and a revenue growth 5.13% for SHC